ArticleJournal of the Chinese Medical Association : JCMA2026
Reimbursement policy and outcomes after transcatheter aortic valve implantation.
Article in Journal of the Chinese Medical Association : JCMA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscatheter aortic valve implantation (TAVI) is an established treatment for severe aortic stenosis. While reimbursement policies significantly expand access, the impact of Taiwan's National Health Insurance (NHI) coverage introduced in February 2021 on patient characteristics and outcomes remains unclear. This study evaluates changes in patient profiles and clinical outcomes before and after NHI reimbursement.
methodsWe compared patient profiles, procedural variables, and clinical outcomes, including 30-day complications and 1-year all-cause mortality, cardiovascular death, and rehospitalization for heart failure (HF). Risk was stratified using the Society of Thoracic Surgeons (STS) score.
resultsWe analyzed 467 patients undergoing TAVI at a tertiary referral center between May 2010 and April 2024. Patients were divided into pre-reimbursement (n = 258) and post-reimbursement (n = 209) groups. Reimbursement was associated with a shift toward higher-risk patients, reflected by an increase in median STS scores (5.9%-7.2%, p = 0.002) and a greater proportion of patients with STS scores ≥8% (44.0% vs 31.8%, p = 0.019). Post-reimbursement patients had a higher prevalence of dialysis (17.7% vs 7.6%, p = 0.001) and more commonly underwent valve-in-valve TAVI for degenerated bioprosthetic valves (8.4% vs 2.7%, p = 0.007). Despite this higher-risk profile, hospital stay was significantly shorter post-reimbursement (7.0 vs 12.0 days, p < 0.001). Valve Academic Research Consortium-3 (VARC-3) defined 30-day outcomes were similar, except for reduced acute kidney injury in post-reimbursement patients (1.0% vs 6.6%, p = 0.021). One-year mortality was unchanged, but HF rehospitalization decreased significantly (2.9% vs 8.1%, p = 0.017). After multivariable adjustment, high STS risk (≥8%) independently predicted worse 1-year outcomes.
conclusionIn this single-treatment group experience, NHI reimbursement in Taiwan expanded TAVI access to higher-risk patients without compromising short- or mid-term mortality, and was associated with reduced heart failure readmission, especially among high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.